Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has issued a correction disclosure regarding its Letter of Intent (LOI) for a biopharmaceutical contract manufacturing agreement with a Europe-based pharmaceutical company, extending the disclosure postponement deadline for the counterparty’s identity from December 31, 2024, to December 31, 2030, upon the customer’s request.
📊 [Key Disclosure Details & Financial Figures]
- Disclosure Title: (Correction) Major Management Matters Related to Investment Decisions
- Original Filing Date: December 23, 2021
- Reason for Correction: Change in disclosure postponement date upon customer request
- Key Correction Items:
- Contract Period: (Before) 2021.10.30 – 2024.12.31 ➔ (After) Deleted
- Expected Counterparty Disclosure Date: (Before) Prior to December 31, 2024 ➔ (After) Prior to December 31, 2030 (Definitive contract expiration date)
- Postponement Deadline: (Before) December 31, 2024 ➔ (After) December 31, 2030
- LOI Details (As Revised in Filing):
- Title: Signing of Letter of Intent for Biopharmaceutical Contract Manufacturing Agreement
- Counterparty: Pharmaceutical company based in Europe
- Contract Amount: KRW 91,369,732,137 (USD 76,703,939, applied exchange rate KRW 1,191.20 per USD on initial disclosure date Dec 23, 2021)
- LOI Signing Date: October 30, 2021
- Contract Amount to Revenue Ratio: 7.84% (Based on recent annual revenue of KRW 1,164,776,873,641 at initial disclosure)
- Disclosure Postponement Details:
- Postponement Item: Contract Counterparty
- Reason for Postponement: Business confidentiality
- Postponement Deadline: December 31, 2030
- Other Important Details:
- The contract amount reflects an increase of USD 20,122,939 from the previous disclosure (USD 56,581,000) to USD 76,703,939 upon customer request.
- The counterparty is scheduled to be disclosed prior to December 31, 2030, subject to change.
- Related Disclosures:
- December 23, 2021: Major Management Matters Related to Investment Decisions
- Multiple correction filings between March 31, 2022, and August 29, 2024
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Postponement Extension and Schedule for Counterparty Disclosure
This correction disclosure provides notice that the confidentiality postponement deadline for the counterparty’s identity under the biopharmaceutical LOI with a Europe-based company has been extended to December 31, 2030, at the client’s request.
Tracking subsequent official filings regarding the disclosure postponement schedule and counterparty details is essential.
Relevant developments can be verified in subsequent official disclosures and periodic filings.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
